PMP22 and Charcot-Marie-Tooth disease type 1A: Hence, in the present study, we tested the hypothesis that PXT3003 treatment downregulates Pmp22 during the critical time window of Schwann cell differentiation and can overcome the known impaired peripheral nerve development in CMT1A.